Immix Biopharma (NASDAQ:IMMX) Earns Outperform Rating from Analysts at Lifesci Capital

Equities researchers at Lifesci Capital assumed coverage on shares of Immix Biopharma (NASDAQ:IMMX) in a report released on Wednesday,Benzinga reports. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Lifesci Capital’s price target would indicate a potential upside of 102.19% from the stock’s previous close.

Other research analysts have also issued reports about the company. Morgan Stanley assumed coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Tuesday, April 21st. Citizens Jmp reiterated a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a report on Friday, March 27th. Mizuho lifted their target price on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Finally, Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.40.

Immix Biopharma Stock Performance

Shares of NASDAQ IMMX traded up $0.66 during trading on Wednesday, reaching $9.40. The stock had a trading volume of 1,260,868 shares, compared to its average volume of 972,400. Immix Biopharma has a fifty-two week low of $1.94 and a fifty-two week high of $11.61. The business’s 50-day moving average price is $9.20 and its 200-day moving average price is $7.68. The company has a market cap of $511.29 million, a P/E ratio of -10.21 and a beta of 0.10.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. Analysts forecast that Immix Biopharma will post -0.7 EPS for the current fiscal year.

Institutional Trading of Immix Biopharma

Institutional investors have recently bought and sold shares of the business. Allworth Financial LP purchased a new stake in Immix Biopharma during the 4th quarter worth about $30,000. Mathes Company Inc. purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at about $56,000. Balyasny Asset Management L.P. purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at about $67,000. Kera Capital Partners Inc. purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at about $68,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at about $112,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.